Andreas Friedl

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1929437/publications.pdf

Version: 2024-02-01

29 3,072 22 27 27 papers citations h-index g-index

30 30 30 30 4500

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Photocleavable Surfactant-Enabled Extracellular Matrix Proteomics. Analytical Chemistry, 2020, 92, 15693-15698.	6.5	24
2	Antiestrogen Therapy Increases Plasticity and Cancer Stemness of Prolactin-Induced $\text{ERl}_{\pm+}$ Mammary Carcinomas. Cancer Research, 2018, 78, 1672-1684.	0.9	21
3	Collagen Alignment as a Predictor of Recurrence after Ductal Carcinoma <i>In Situ</i> . Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 138-145.	2.5	94
4	Syndecan-1 induction in lung microenvironment supports the establishment of breast tumor metastases. Breast Cancer Research, 2018, 20, 66.	5.0	35
5	Syndecan-1-Induced ECM Fiber Alignment Requires Integrin $\hat{l}\pm\nu\hat{l}^2$ 3 and Syndecan-1 Ectodomain and Heparan Sulfate Chains. PLoS ONE, 2016, 11, e0150132.	2.5	39
6	A Positive Feedback Loop Between Prolactin and Stat5 Promotes Angiogenesis. Advances in Experimental Medicine and Biology, 2015, 846, 265-280.	1.6	22
7	STAT5 and Prolactin Participate in a Positive Autocrine Feedback Loop That Promotes Angiogenesis. Journal of Biological Chemistry, 2013, 288, 21184-21196.	3.4	45
8	Functional Screen of Paracrine Signals in Breast Carcinoma Fibroblasts. PLoS ONE, 2012, 7, e46685.	2.5	33
9	Angiogenesis Induced by Signal Transducer and Activator of Transcription 5A (STAT5A) Is Dependent on Autocrine Activity of Proliferin. Journal of Biological Chemistry, 2012, 287, 6490-6502.	3.4	23
10	Syndecan-1 in Breast Cancer Stroma Fibroblasts Regulates Extracellular Matrix Fiber Organization and Carcinoma Cell Motility. American Journal of Pathology, 2011, 178, 325-335.	3.8	119
11	Aligned Collagen Is a Prognostic Signature for Survival in Human Breast Carcinoma. American Journal of Pathology, 2011, 178, 1221-1232.	3.8	1,026
12	Colorectal cancer desmoplastic reaction affects tumor cell invasion. FASEB Journal, 2011, 25, 915.6.	0.5	0
13	Proteoglycans: Master modulators of paracrine fibroblast–carcinoma cell interactions. Seminars in Cell and Developmental Biology, 2010, 21, 66-71.	5. 0	12
14	The Transcription Factor REST Is Lost in Aggressive Breast Cancer. PLoS Genetics, 2010, 6, e1000979.	3.5	78
15	Signal Transducers and Activators of Transcription Mediate Fibroblast Growth Factor–Induced Vascular Endothelial Morphogenesis. Cancer Research, 2009, 69, 1668-1677.	0.9	65
16	Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Research and Treatment, 2008, 108, 389-397.	2.5	190
17	Membrane Type 1 Matrix Metalloproteinase–Mediated Stromal Syndecan-1 Shedding Stimulates Breast Carcinoma Cell Proliferation. Cancer Research, 2008, 68, 9558-9565.	0.9	64
18	Shedding of Syndecan-1 by Stromal Fibroblasts Stimulates Human Breast Cancer Cell Proliferation via FGF2 Activation. Journal of Biological Chemistry, 2007, 282, 14906-14915.	3.4	107

#	Article	IF	CITATIONS
19	Glypican-1 Is Frequently Overexpressed in Human Gliomas and Enhances FGF-2 Signaling in Glioma Cells. American Journal of Pathology, 2006, 168, 2014-2026.	3.8	139
20	Effects of a monoclonal anti-αvβ3 integrin antibody on blood vessels—A pharmacodynamic study. Investigational New Drugs, 2006, 25, 49-55.	2.6	32
21	Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype. Breast Cancer Research and Treatment, 2006, 98, 91-98.	2.5	103
22	Phase I Trial of a Monoclonal Antibody Specific for $\hat{l}\pm\nu\hat{l}^2$ 3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion. Clinical Cancer Research, 2005, 11, 7851-7860.	7.0	147
23	Induction of Syndecan-1 Expression in Stromal Fibroblasts Promotes Proliferation of Human Breast Cancer Cells. Cancer Research, 2004, 64, 612-621.	0.9	127
24	Syndecan-1 accumulates in lysosomes of poorly differentiated breast carcinoma cells. Matrix Biology, 2003, 22, 163-177.	3.6	48
25	Heparan Sulfate Proteoglycans as Regulators of Fibroblast Growth Factor-2 Signaling in Brain Endothelial Cells. Journal of Biological Chemistry, 2003, 278, 16045-16053.	3.4	101
26	Heparan Sulfate Proteoglycans as Regulators of Fibroblast Growth Factor-2 Receptor Binding in Breast Carcinomas. American Journal of Pathology, 2002, 160, 185-194.	3.8	139
27	Differential ability of heparan sulfate proteoglycans to assemble the fibroblast growth factor receptor complex <i>in situ</i> . FASEB Journal, 2000, 14, 137-144.	0.5	102
28	Heterogeneous expression of the lipocalin NGAL in primary breast cancers. , 1998, 79, 565-572.		135
29	Heterogeneous expression of the lipocalin NGAL in primary breast cancers. International Journal of Cancer, 1998, 79, 565-572.	5.1	2